A new oral approach to GLP-1 treatment helped adults with obesity or overweight lose as much as 12 percent of their body weight over 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine. A GLP-1 Drug That Comes as a PillAleniglipron differs from currently available GLP-1 drugs (glucagon-like peptide 1) such as semaglutide, which is sold as Ozempic and Wegovy. GLP-1 drugs work by mimicking the naturally occurring GLP-1 hormone. Small-molecule GLP-1 drugs could address some of those limitations because they can be taken orally and may be easier to manufacture in large quantities, Kushner said. By week 36, average body-weight change from baseline reached −9.0 percent in the 45 milligrams group, -10.7 percent in the 90 milligrams group and -12.1 percent in the 120 milligrams group.